HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: We compared the effect of 4SC-202 to Vorinostat, a broad spectrum HDAC inhibitor which is currently used to treat cutaneous T-cell lymphoma, on tumor growth and metastasis.